GFAP and Cognitive impairment: Reactive astrocytes, as measured by cerebrospinal fluid (CSF) levels of glial fibrillary acidic protein (GFAP), have been shown to mediate the effect of Aβ on tau and drive downstream neurodegeneration and cognitive impairment in patients with AD [24] and preclinical AD.